Vertex Announces European Commission Approval for KALYDECO® (ivacaftor) as First and Only CFTR Modulator to Treat Eligible Infants With Cystic Fibrosis as Early as Four Months of AgeBusiness Wire • 11/05/20
Vertex, Neurocrine: Are These Out Of Favor Healthcare Stocks A Buy As Vaccine Nears?Forbes • 11/03/20
Vertex Pharmaceuticals, Inc. (VRTX) CEO Reshma Kewalramani on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 10/30/20
Were These Hedge Funds Right About Selling Vertex Pharmaceuticals Incorporated (VRTX)?Insider Monkey • 10/26/20
Is Vertex Pharmaceuticals (VRTX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 10/20/20